Back to top

messenger-rna: Archive

Zacks Equity Research

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.

SNYNegative Net Change BIIBNegative Net Change NVAXPositive Net Change CSTLNegative Net Change

Zacks Equity Research

Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.

BIIBNegative Net Change MRKNegative Net Change MRNANegative Net Change FOLDPositive Net Change

Sundeep Ganoria

Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.

GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNANegative Net Change

Zacks Equity Research

Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.

SNYNegative Net Change PFENegative Net Change MRNANegative Net Change NVAXPositive Net Change

Sundeep Ganoria

Moderna Stock Falls 20% in a Month: Time to Sell or Hold?

Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.

GSKNegative Net Change PFENegative Net Change MRNANegative Net Change

Zacks Equity Research

Here's Why You Should Retain Merit Medical Stock in Your Portfolio

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

DGXPositive Net Change UHSNegative Net Change BAXNegative Net Change MMSINegative Net Change

Zacks Equity Research

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

SNYNegative Net Change GSKNegative Net Change MRKNegative Net Change MRNANegative Net Change